Core Insights - Hanbang Technology's stock decreased by 0.83% on September 22, with a trading volume of 22.01 million yuan [1] - The company reported a net financing purchase of 1.136 million yuan on the same day, with a total financing balance of 92.68 million yuan, accounting for 12.27% of its market capitalization [1] Financing Overview - On September 22, Hanbang Technology had a financing buy amount of 4.101 million yuan and a financing repayment of 2.965 million yuan [1] - The company had no short selling activity on the same day, with a short selling balance of 0 yuan [1] Company Profile - Hanbang Technology, established on October 28, 1998, is located in Huai'an Economic and Technological Development Zone, Jiangsu Province [1] - The company specializes in providing separation and purification equipment, consumables, application technology services, and related technical solutions for the pharmaceutical and life sciences sectors [1] - The revenue composition includes 70.99% from small molecule drug separation and purification equipment, 22.94% from large molecule drug separation and purification equipment, and 6.07% from other sources [1] Financial Performance - As of June 30, 2025, Hanbang Technology reported a revenue of 349 million yuan, a year-on-year increase of 5.99%, while the net profit attributable to shareholders decreased by 26.24% to 27.7976 million yuan [2] - The number of shareholders decreased by 48.43% to 9,372, while the average circulating shares per person increased by 93.92% to 1,764 shares [2] Shareholder Information - As of June 30, 2025, the largest circulating shareholder is Dongfanghong Medical Upgrade Stock Initiation A (015052), holding 483,700 shares as a new shareholder [2]

Group 1 - The company announced a profit distribution plan for the first half of 2025, proposing a cash dividend of 0.1 yuan per share (tax included) [2] - The record date for the dividend is set for September 26, 2025, with the ex-dividend date and payment date both on September 29, 2025 [2]

2025年半年度权益分派实施公告 江苏汉邦科技股份有限公司 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688755 证券简称：汉邦科技 公告编号：2025-032 重要内容提示： 每股现金红利0.1元（含税） 相关日期 | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/9/26 | 2025/9/29 | 2025/9/29 | 一、 通过分配方案的股东会届次和日期 本次利润分配方案经公司2025 年 9 月 11 日的2025年第二次临时股东会审议通 过。 二、 分配方案 1. 发放年度：2025年半年度 2. 分派对象： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/9/26 | 2025/9/29 | 2025/9/29 | 四、 分配实施办法 1. 实施办法 （1）无限售条件流通股的红利委托中国结算上海分公司通过其资金清算系统 向股权登记日上海证券交易所收市后登记在册并在上海 ...

Core Insights - On September 18, Hanbang Technology experienced a decline of 1.69% with a trading volume of 53.52 million yuan [1] - The company had a net financing buy of -0.94 million yuan on the same day, with a total financing and securities balance of 92.89 million yuan [1] Financing Overview - On September 18, Hanbang Technology had a financing buy of 10.95 million yuan, with a current financing balance of 92.89 million yuan, accounting for 12.21% of the circulating market value [1] - There were no shares repaid or sold in the securities lending market on that day, resulting in a securities lending balance of 0.00 yuan [1] Company Profile - Hanbang Technology, established on October 28, 1998, is located in Huai'an Economic and Technological Development Zone, Jiangsu Province [1] - The company specializes in providing separation and purification equipment, consumables, application technology services, and related technical solutions for the pharmaceutical and life sciences sectors [1] - The revenue composition includes: 70.99% from small molecule drug separation and purification equipment, 22.94% from large molecule drug separation and purification equipment, and 6.07% from other sources [1] Financial Performance - As of June 30, the number of shareholders for Hanbang Technology was 9,372, a decrease of 48.43% from the previous period [2] - The average circulating shares per person increased by 93.92% to 1,764 shares [2] - For the first half of 2025, the company reported a revenue of 349 million yuan, a year-on-year increase of 5.99%, while the net profit attributable to the parent company was 27.80 million yuan, a decrease of 26.24% year-on-year [2] - As of June 30, the largest circulating shareholder was Dongfanghong Medical Upgrade Stock Initiation A (015052), holding 483,700 shares as a new shareholder [2]

Core Insights - Hanbang Technology's stock price increased by 0.04% on September 17, with a trading volume of 29.5371 million yuan [1] - The company experienced a net financing outflow of 2.5878 million yuan on the same day, with a total financing and securities balance of 93.8258 million yuan [1] - As of June 30, 2025, Hanbang Technology reported a revenue of 349 million yuan, a year-on-year increase of 5.99%, while net profit decreased by 26.24% to 27.7976 million yuan [2] Financing and Trading Data - On September 17, Hanbang Technology had a financing buy amount of 2.8171 million yuan and a financing repayment of 5.4048 million yuan, resulting in a net financing buy of -2.5878 million yuan [1] - The current financing balance of 93.8258 million yuan accounts for 12.12% of the company's market capitalization [1] - No shares were sold or repaid in the securities lending market on September 17, with a total securities lending balance of 0 [1] Shareholder Information - As of June 30, 2025, the number of shareholders for Hanbang Technology was 9,372, a decrease of 48.43% from the previous period [2] - The average number of circulating shares per shareholder increased by 93.92% to 1,764 shares [2] - The largest circulating shareholder is Dongfanghong Medical Upgrade Stock Initiation A (015052), holding 483,700 shares as a new shareholder [2] Business Overview - Hanbang Technology, established on October 28, 1998, specializes in providing separation and purification equipment, consumables, application technology services, and related technical solutions for the pharmaceutical and life sciences sectors [1] - The revenue composition of the company includes 70.99% from small molecule drug separation and purification equipment, 22.94% from large molecule drug separation and purification equipment, and 6.07% from other sources [1]

中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为江苏汉 邦科技股份有限公司（以下简称"汉邦科技"或"公司"或"上市公司"）首次 公开发行股票并在科创板上市的保荐人。根据《证券发行上市保荐业务管理办 法》、《上海证券交易所科创板股票上市规则》等相关规定，中信证券履行持续 督导职责，并出具本持续督导半年度跟踪报告。 一、持续督导工作概述 1、保荐人制定了持续督导工作制度，制定了相应的工作计划，明确了现场 检查的工作要求。 2、保荐人已与公司签订保荐协议，该协议已明确了双方在持续督导期间的 权利义务，并报上海证券交易所备案。 中信证券股份有限公司 关于江苏汉邦科技股份有限公司 2025 年半年度持续督导跟踪报告 3、本持续督导期间，保荐人通过与公司的日常沟通、现场回访等方式开展 持续督导工作，并于 2025 年 8 月 25 日对公司进行了现场检查。 4、本持续督导期间，保荐人根据相关法规和规范性文件的要求履行持续督 导职责，具体内容包括： （1）查阅公司章程、三会议事规则等公司治理制度、三会会议材料； （2）查阅公司财务管理、会计核算和内部审计等内部控制制度； （3）查阅公司与控股股东、实际控制人及其 ...

据汉邦科技招股说明书披露，思拓凡此前以汉邦科技的自动轴向压缩层析柱（ACC系列）、自动匀浆 罐（STK系列）等产品侵犯其三项发明专利为由提起诉讼，索赔金额累计超1650万元。其中，针对"色 谱柱"专利的诉讼（专利侵权案2）已出现决定性结果，国家知识产权局宣告该专利权全部无效，最高人 民法院据此终审裁定撤销原审判决，驳回思拓凡起诉。 另一起涉及"柱装填方法"的诉讼（专利侵权案1）中，一审法院曾判定汉邦科技不构成侵权，思拓凡不 服判决提起上诉，目前案件正在最高人民法院审理过程中。第三起关于"分离介质浆料罐"专利的诉讼 （专利侵权案3），国家知识产权局审查并宣告"分离介质浆料罐"专利权全部无效。 本报讯 （记者陈红）近日，江苏汉邦科技股份有限公司（以下简称"汉邦科技"）在与思拓凡瑞典有限 公司（以下简称"思拓凡"）的三起专利侵权诉讼中取得阶段性重大进展，其中两起涉及"色谱柱"及"分 离介质浆料罐"的发明专利，中华人民共和国国家知识产权局（以下简称"国家知识产权局"）审查并宣 告"色谱柱""分离介质浆料罐"专利权全部无效。 另一起"柱装填方法"专利诉讼案件，南京市中级人民法院认定汉邦科技不构成侵权，仍在等待最高人民 ...

9月9日，汉邦科技(688755.SH)披露公告称，公司与思拓凡(Cytiva)之间的三起专利侵权诉讼取得阶段性 进展。根据招股说明书及临时公告，其中两起涉案专利已被国家知识产权局宣告无效，另一项诉讼仍在 最高人民法院审理中。 公告显示，双方纠纷涉及自动轴向压缩层析柱、自动匀浆罐等相关产品。"色谱柱"专利诉讼中，南京市 中级人民法院一审曾判定汉邦科技侵权，但随后该专利被国家知识产权局宣告无效，最高人民法院终审 裁定撤销原判，驳回思拓凡起诉，该案已结案。"分离介质浆料罐"专利诉讼中，涉案专利亦被宣告无 效。"柱装填方法"专利诉讼中，一审判定汉邦科技不构成侵权，思拓凡不服上诉，目前该案正在最高人 民法院审理，尚无终审结果。 公司表示，作为以色谱技术为核心的高新技术企业，二十余年深耕色谱技术，公司始终以"打造国际色 谱行业第一品牌"为目标，构建起覆盖"色谱柱技术—系统集成—应用解决方案"的全链条创新体系。(齐 和宁) 汉邦科技长期专注色谱技术研发，已形成涵盖色谱柱技术、系统集成及应用解决方案的技术体系，并成 功突破了色谱线性放大等"卡脖子"技术，实现了从克级到千克级分离纯化的技术应用，相关成果已用于 抗体、疫苗、胰 ...

Group 1 - The company held its second board meeting on September 11, 2025, where all nine directors attended and agreed to waive the notice period for the meeting [2][3] - Zhang Dabin was elected as the chairman of the second board of directors with unanimous approval [3][6] - The board established several specialized committees, including the audit committee, nomination committee, compensation and assessment committee, and strategy committee, with a term of three years [4][26] Group 2 - The board approved the appointment of Zhang Dabin as the general manager (CEO) of the company, effective immediately [4][27] - The board appointed Tang Yefeng as the secretary of the board, with a term aligned with the board's term [8][28] - The company appointed several vice presidents, including Li Shengying, Tang Yefeng, Jin Xinliang, Liu Genshui, and Yan Zhong, with the same term as the board [11][27] Group 3 - The board approved the appointment of Gu Bin as the financial director, effective immediately [14][27] - The company appointed Xie Yuxin as the securities affairs representative, with a term aligned with the board's term [17][28] - The board approved the addition and revision of certain governance systems to enhance operational standards and protect shareholder rights [19][50]

（文章来源：证券日报） 证券日报网讯 9月11日晚间，汉邦科技发布公告称，公司聘任张大兵先生为公司总经理（总裁）。 ...